|1.||Wang, Lei: 1 article (08/2015)|
|2.||Yu, Fanzong: 1 article (08/2015)|
|3.||Wu, Chunli: 1 article (08/2015)|
|4.||Jia, Benli: 1 article (08/2015)|
|5.||Wan, Shengyun: 1 article (08/2015)|
|6.||Geng, Xiaoping: 1 article (08/2015)|
|7.||Hou, Hui: 1 article (08/2015)|
|8.||Weiquan, Liu: 1 article (06/2014)|
|9.||Jigui, Wang: 1 article (06/2014)|
|10.||Jiazeng, Sun: 1 article (06/2014)|
|1.||Septic Shock (Toxic Shock Syndrome)
02/01/2004 - "Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock."
02/01/2004 - "To investigate the efficacy of imipenem, piperacillin combined with cecropin B in the prevention of lethality in 2 rat models of septic shock. "
09/01/2001 - "To investigate the efficacy of three cecropins, cecropin A, cecropin B, and cecropin P1, in preventing lethality in a rat model of septic shock. "
|2.||Wounds and Injuries (Trauma)
12/01/2006 - "The cecropin B possesses obvious anti-bacterial effect on the Pseudomonas Aeruginosa infected wounds of ICR mice, and it can reduce the mortality."
05/01/2004 - "HB-107, a nonbacteriostatic fragment of the antimicrobial peptide cecropin B, accelerates murine wound repair."
12/01/2006 - "To investigate the antibacterial effect of a particular antimicrobial peptide Cecropin B(CB) on Pseudomonas aeruginosa infection of wound in mice. "
12/01/2006 - "[The antibacterial effect of cecropin B on pseudomonas aeruginosa infection of wounds in mice]."
05/01/2004 - "HB-107, a peptide lacking antimicrobial activity and originally derived from the antimicrobial cecropin B, showed up to 64 percent improvement in wound repair compared to scrambled peptide and vehicle controls, an effect comparable to treatment with recombinant human platelet-derived growth factor-BB (formulated as Regranex). "
06/01/2002 - "Also, when challenged in tanks with Edwardsiella ictaluri, the causative agent of enteric septicemia of catfish, the percentage of transgenic individuals containing catfish IG leader cecropin B construct that survived (40.7%) was significantly greater (P <0.01) than that of nontransgenic controls (14.8%). "
08/01/2004 - "We used the cell-attached patch to study the effect of cecropin B (CB; having one hydrophobic and one amphipathic alpha-helix) and its derivative, cecropin B3 (CB3; having two hydrophobic alpha-helices) on the membrane of Ags cancer cells. "
06/28/2014 - "Potentiation of Apoptin-induced apoptosis by Cecropin B-like antibacterial peptide ABPs1 in human HeLa cervical cancer cell lines is associated with membrane pore formation and caspase-3 activation."
11/01/1998 - "A comparison between IC50s of cecropin B on tumor cells such as KG-1 leukemia and Ags stomach carcinoma and non-tumor cells like fibroblasts and red blood cells was conducted. "
08/29/1997 - "Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells."
10/01/2013 - "In this study, cecropin B (CecB), a cationic peptide, was immobilized onto the surfaces of titanium substrates to improve their cytocompatibility and reduce inflammation responses. "
10/01/2013 - "Surface functionalization of titanium substrates with cecropin B to improve their cytocompatibility and reduce inflammation responses."
|4.||platelet-derived growth factor BB (becaplermin)
|8.||Mafenide (Mafenide Acetate)
|9.||Caspase 3 (Caspase-3)